chassis
发表于 2025-3-25 03:29:23
http://reply.papertrans.cn/43/4256/425552/425552_21.png
CHART
发表于 2025-3-25 09:45:02
Book 2017 molecular aspects. Research on the pathogenesis of hematological disorders in children has made remarkable strides; especially molecular target therapy has shown outstanding effects in refractory and conventional therapies for childhood leukemia. The findings presented in this book will broaden rea
搜寻
发表于 2025-3-25 15:30:22
http://reply.papertrans.cn/43/4256/425552/425552_23.png
Isthmus
发表于 2025-3-25 16:11:27
http://reply.papertrans.cn/43/4256/425552/425552_24.png
JADED
发表于 2025-3-25 20:36:53
Primary Hemophagocytic Lymphohistiocytosisn lymphocyte cytotoxic function leads to abnormal activation of T cells and subsequent release of inflammatory cytokines. Herein, recent advances in genetics, pathophysiology, diagnostic procedure, and clinical management of primary HLH are reviewed.
神圣将军
发表于 2025-3-26 03:44:52
http://reply.papertrans.cn/43/4256/425552/425552_26.png
URN
发表于 2025-3-26 07:31:31
Langerhans Cell Histiocytosisment of childhood LCH remain: how do clinicians rescue patients with risk-organ involvement that do not respond to first-line therapy, and how do they reduce and treat central nervous system-related consequences such as central diabetes insipidus and neurodegeneration? More research is needed to resolve these treatment-related issues.
共和国
发表于 2025-3-26 09:17:43
Acute Lymphoblastic Leukemiae 1960s to approximately 90% nowadays. Recent advance in genomic analyses is rapidly increasing our understanding of the pathobiology of ALL, which may lead to a development of novel molecular targeted therapy and finally to overcome the disease in future.
beta-carotene
发表于 2025-3-26 15:47:30
http://reply.papertrans.cn/43/4256/425552/425552_29.png
Arthritis
发表于 2025-3-26 20:11:52
ield of pediatric hematology and oncology seeking to broaden their understanding and keep up with the latest developments. It will also beof interest to the parents of pediatric patients, and to co-medical staffs..978-981-10-9992-2978-981-10-3886-0